CTXR Citius Pharmaceuticals, Inc.: Earnings per share for the last 12 months

Quality control automation in Citius Pharmaceuticals production contrasts with the absence of geopolitical risks due to its operations within the US legal framework. The TTM EPS dynamics reconcile these aspects, where the 57.20 mark serves as a key metric. The business relies on the infection control market, offering the Mino-Lok solution to oncology centers for catheter salvage.
CTXR (Citius Pharma): analytical breakdowns and indicator data

This indicator measures the trailing twelve-month (TTM) earnings per share (EPS) dynamics, allowing for the elimination of GAAP accounting distortions to assess actual capital inflows. By analyzing comparable annual EPS TTM growth, an investor determines the operational resilience of Citius Pharmaceuticals (CTXR), which is critical when scaling the distribution of specialized catheter solutions within the intensive care and oncology segments.